Clinical Trial

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Study acronym: PSI-Immune
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-28; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2025-10-31
Trial Details
NCT Number NCT07223424
Lead Sponsor Diwakar Davar
Conditions Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma +4 more
Enrollment 880 participants
Start Date 2025-11-04
Primary Completion 2030-11-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-16